M.Sc, Molecular and Cancer biology, Paris-Sud University, France
Ph.D, Oncology, cell and molecular biology, Paris-Sud University, France
MBA, Pharmaceutical & Healthcare Management, Institut Supérieur de Commerce de Paris, France
Post-Doctoral Fellow, Gleave team, Vancouver Prostate Centre
Post-Doctoral Fellow, Daugaard team, Vancouver Prostate Centre
Research Scientist, Vancouver Prostate Centre
Adjunct Professor, Faculty of Medicine, University of British Columbia
Dr. Nader Al Nakouzi is a Research Scientist at the Vancouver Prostate Centre. He obtained a DPhil (PhD) in Cancer Biology from the University of Paris-XI in 2011 and a specialized MBA in Pharmaceutical & Healthcare Management from ISC-Paris. From 2012 to 2016, he pursued his postdoctoral training With Drs. Martin Gleave and Mads Daugaard.
Dr. Al Nakouzi has a background in molecular and cell biology, and 10 years of experience in development of cancer therapeutics and molecular mechanisms of drug resistance. He was mainly involved in elucidating the mechanisms of resistance of Docetaxel and Custirsen in prostate cancer. He also worked on the development of HSP27 inhibitors and VAR2-drug conjugates.
Dr. Al Nakouzi’s primary research goal is to identify and characterize novel drug targets to treat late-stage prostate cancer. He works very closely with Dr. Mads Daugaard to study the glycosaminoglycan modifications in cancer and to dissect the clinical relevance of these modifications during the disease progression.
Dr. Al Nakouzi has published original research in top-tier scientific journals and received numerous national and international awards and competitive international funding, such as ARC-Doctoral award-France; AACR-training award, Terry Fox Foundation Scholar-in-training award, MITACS Elevate, CUA-Astellas, Canadian Institutes of Health Research (CIHR-2017), and SPORE-NIH-2018.